X
<

Pfizer’s 2017 Performance in Review

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 2
Pfizer’s 2017 Performance in Review PART 2 OF 12

Inside Pfizer’s Vaccines Performance in 4Q17 and 2017

PFE’s vaccine revenue trends

In 4Q17, Pfizer (PFE) generated revenues of $1.6 billion from the sale of vaccines, which reflected a ~8% rise on a YoY (year-over-year) basis. In 4Q17, in the US and in international markets, vaccines generated revenues of $789 million and $828 million, respectively, compared with $846 million and $649 million in 4Q16.

In 4Q17, in international markets, Pfizer’s vaccines witnessed a 28% rise on a YoY basis. In emerging markets, Pfizer’s vaccines generated revenues of $403 million, which reflected a ~53% rise on a YoY basis in 4Q17.

Inside Pfizer’s Vaccines Performance in 4Q17 and 2017

Interested in PFE? Don't miss the next report.

Receive e-mail alerts for new research on PFE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In fiscal 2017, Pfizer’s vaccines generated revenues of $6.0 billion, which reflected a ~1% decline on a YoY basis. In 2017, in the US and in international markets, Pfizer’s vaccines generated revenues of $3.4 billion and $2.26 billion, respectively, compared with $3.6 billion and $2.1 billion in 2016.

Prevnar 13 revenue trends

In 4Q17, Pfizer’s Prevnar 13 reported revenues of $1.5 billion, which represents a ~8% rise on a YoY basis and a 1% rise quarter-over-quarter. In 4Q17, in the US and in international markets, Prevnar 13 reported revenues of $780 million and $753 million, respectively, compared with $835 million and $531 million in 4Q16.

In fiscal 2017, Prevnar reported revenues of $5.6 billion, which represents a ~2% fall on a YoY basis. In 2017, in the US and in international markets, Prevnar 13 reported revenues of $3.3 billion and $2.3 billion, respectively, compared with $3.6 billion and $2.1 billion in 2016.

FSME/IMMUN-TicoVac revenue trends

In 4Q17, Pfizer’s FSME/IMMUN-TicoVac vaccine reported revenues of $15 million, which reflected a ~22% rise on a YoY basis. In fiscal 2017, Pfizer’s FSME/IMMUN-TicoVac vaccine reported revenues of $134 million, compared with $114 million in 2016, reflecting an 18% rise on a YoY basis.

Notably, in 4Q17, vaccine peers GlaxoSmithKline (GSK), Merck (MRK), and Sanofi (SNY) reported revenues of $10.1 billion, $10.4 billion, and $10.2 billion, respectively.

In the next part of this series, we’ll check in with Pfizer’s position in the biosimilar market after 2017.

X

Please select a profession that best describes you: